» Articles » PMID: 12086933

Glucokinase is the Likely Mediator of Glucosensing in Both Glucose-excited and Glucose-inhibited Central Neurons

Overview
Journal Diabetes
Specialty Endocrinology
Date 2002 Jun 28
PMID 12086933
Citations 114
Authors
Affiliations
Soon will be listed here.
Abstract

Specialized neurons utilize glucose as a signaling molecule to alter their firing rate. Glucose-excited (GE) neurons increase and glucose-inhibited (GI) neurons reduce activity as ambient glucose levels rise. Glucose-induced changes in the ATP-to-ADP ratio in GE neurons modulate the activity of the ATP-sensitive K(+) channel, which determines the rate of cell firing. The GI glucosensing mechanism is unknown. We postulated that glucokinase (GK), a high-Michaelis constant (K(m)) hexokinase expressed in brain areas containing populations of GE and GI neurons, is the controlling step in glucosensing. Double-label in situ hybridization demonstrated neuron-specific GK mRNA expression in locus ceruleus norepinephrine and in hypothalamic neuropeptide Y, pro-opiomelanocortin, and gamma-aminobutyric acid neurons, but it did not demonstrate this expression in orexin neurons. GK mRNA was also found in the area postrema/nucleus tractus solitarius region by RT-PCR. Intracarotid glucose infusions stimulated c-fos expression in the same areas that expressed GK. At 2.5 mmol/l glucose, fura-2 Ca(2+) imaging of dissociated ventromedial hypothalamic nucleus neurons demonstrated GE neurons whose intracellular Ca(2+) oscillations were inhibited and GI neurons whose Ca(2+) oscillations were stimulated by four selective GK inhibitors. Finally, GK expression was increased in rats with impaired central glucosensing (posthypoglycemia and diet-induced obesity) but was unaffected by a 48-h fast. These data suggest a critical role for GK as a regulator of glucosensing in both GE and GI neurons in the brain.

Citing Articles

Dorzagliatin: A Breakthrough Glucokinase Activator Coming on Board to Treat Diabetes Mellitus.

Raju R, Prabath I, Chandrasekaran I, Varadarajan S Cureus. 2024; 16(7):e65708.

PMID: 39211666 PMC: 11361462. DOI: 10.7759/cureus.65708.


New-Generation Glucokinase Activators: Potential Game-Changers in Type 2 Diabetes Treatment.

Haddad D, Dsouza V, Al-Mulla F, Madhoun A Int J Mol Sci. 2024; 25(1).

PMID: 38203742 PMC: 10779250. DOI: 10.3390/ijms25010571.


Brain Regulation of Cardiac Function during Hypoglycemia.

Chambers M, Nuibe E, Reno-Bernstein C Metabolites. 2023; 13(10).

PMID: 37887414 PMC: 10608630. DOI: 10.3390/metabo13101089.


ADGRL1 is a glucose receptor involved in mediating energy and glucose homeostasis.

Chhabra K, Bathina S, Faniyan T, Samuel D, Raza M, de Souza Cordeiro L Diabetologia. 2023; 67(1):170-189.

PMID: 37712955 PMC: 10709246. DOI: 10.1007/s00125-023-06010-6.


Obesity-associated microglial inflammatory activation paradoxically improves glucose tolerance.

Douglass J, Ness K, Valdearcos M, Wyse-Jackson A, Dorfman M, Frey J Cell Metab. 2023; 35(9):1613-1629.e8.

PMID: 37572666 PMC: 10528677. DOI: 10.1016/j.cmet.2023.07.008.